Ticker

No recent analyst price targets found for ITRMF.

Latest News for ITRMF

Iterum Therapeutics Announces Filing of Winding Up Petition

DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up…

GlobeNewsWire • Mar 27, 2026
Iterum Therapeutics Provides Business Update

--Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and…

GlobeNewsWire • Feb 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ITRMF.

No House trades found for ITRMF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top